However, engineered iNK cells were equivalent to WT iNK cells in lysing GBM cells lacking these receptors, namely CD155KO, CD73KO, and double CD155/CD73KO cell lines, demonstrating the specificity of engineered iNK cells for CD73 and CD155 target ligands (Fig. 3D-F). This evidence concerns the gene PVR and glioblastoma.